Company Overview
Snapshot
Founded in January 2019 by Dr. Dorit Dil Nahlieli, Avishai Ben-Tovim, and Yuval Kalev, MDI Health operates with 51–200 employees. The company has raised $30.5 million across 5 funding rounds from 8 investors, with Intel Capital leading a significant A Round in February 2023. This funding is aimed at meeting customer demand and expanding research and development teams.
Business overview
MDI Health develops an AI-driven pharmacology platform designed to optimize personal medication regimens. Its core technology performs multidimensional, context-based analyses of thousands of pharmacological and patient-specific parameters. The platform is utilized by payers and value-based providers to identify high-risk patients for adverse drug events, mitigate these risks in real-time, and implement recommendations. This approach aims to reduce total care costs while enhancing the quality of care within the Digital Healthcare and Medical Decision Support sectors.
Strategic signal
In February 2023, MDI Health secured $20 million in an A Round led by. This investment signals strong investor confidence in MDI Health's AI-driven medication management platform and its potential to address critical challenges in patient safety and healthcare costs. The funding is earmarked for scaling operations to meet growing customer demand and accelerating R&D, indicating a clear trajectory for market expansion and product innovation.
Log in to access full profile ›Company Intelligence Q&A
- What was MDI Health's most recent funding round?
- In February 2023, MDI Health raised $20 million in an A Round. The round was led by Intel Capital and Maverick Ventures Israel.
- What is the primary purpose of MDI Health's AI platform?
- MDI Health's AI-driven pharmacology platform performs multidimensional, context-based analyses of pharmacological and patient-specific parameters to autonomously optimize personal medication regimens. This helps identify high-risk patients for adverse drug events and reduce those risks in real time.
- When did MDI Health launch its end-to-end AI platform for personalized medication?
- In June 2021, MDI Health launched its end-to-end AI platform for personalized medication. Clinical trials conducted at Hadassah University Hospital in Israel demonstrated that the platform provided up to 40% more life-saving patient insights than identified by clinical pharmacists.
- Which investors participated in MDI Health's Seed round?
- In June 2021, MDI Health completed a Seed round led by.
- What was MDI Health's earliest disclosed funding event?
- In August 2019, MDI Health secured Pre-Seed funding. This round was led by Jumpspeed Ventures and included participation from Fresh Fund.